GlassScriptPhysician profile
Leonard N Glade
NPI 1184676744
$9,976.46
in general payments reported to CMS, 2019-2025
43 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $359 · 2021: $230 · 2022: $402 · 2023: $3,536 · 2024: $2,763 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $3,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $3,607.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,220.69 | 2020-2025 | Optis, Diamondback Coronary, Esprit |
| Genzyme Corporation | $792.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $530.48 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $426.09 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boston Scientific Corporation | $397.96 | 2022-2025 | Watchman, Varithena Administration Pack, Ranger |
| Abiomed | $396.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $266.10 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $189.77 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.06 | 2019-2025 | Ofev |
| Verona Pharma, INC. | $125.70 | 2025 | Ohtuvayre |
| Amgen INC. | $120.96 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $109.99 | 2021 | |
| Shockwave Medical, INC | $105.60 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Genentech USA, INC. | $73.40 | 2019-2022 | |
| Electromed, INC. | $72.77 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $69.80 | 2019 | |
| Novo Nordisk INC | $69.10 | 2019-2025 | Ozempic |
| Baxter Healthcare | $68.78 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Calliditas Therapeutics US INC. | $67.91 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $64.46 | 2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $62.05 | 2025 | |
| Ani Pharmaceuticals, INC. | $50.29 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $44.60 | 2025 | Jynarque |
| Surmodics, INC. | $42.53 | 2023-2024 | Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy System |
| Janssen Pharmaceuticals, INC | $39.96 | 2019 | |
| Philips North America LLC | $34.42 | 2025 | Vest Therapy Und, Labosys |
| Pinnacle Biologics, INC | $32.26 | 2025 | Photofrin |
| Ultragenyx Pharmaceutical INC. | $29.67 | 2022 | |
| Seqirus USA INC | $28.59 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $27.60 | 2025 | Neffy |
| Vifor Pharma, INC. | $27.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.73 | 2024 | |
| Mallinckrodt Hospital Products INC. | $20.20 | 2025 | Acthar |
| Phadia US INC. | $20.10 | 2024 | Immunocap |
| Hikma Pharmaceuticals USA | $19.72 | 2024 | Ryaltris |
| Viatris Specialty LLC | $19.55 | 2025 | Yupelri |
| Mylan Specialty L.P. | $19.48 | 2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2024 | Eliquis |
| Esperion Therapeutics, INC. | $18.12 | 2025 | Nexletol |
| Abbvie INC. | $15.98 | 2019 | |
| Shield Therapeutics INC | $14.60 | 2025 | |
| Smith+Nephew, INC. | $14.03 | 2019 | |
| Pfizer INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Glade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.